Progressive Care Announces
Telehealth Partnership With EagleForce Health to Drive myVax
Digital Passport for COVID-19 Testing and Vaccination
MIAMI, FL -- February 16, 2021 -- InvestorsHub NewsWire --
Progressive Care Inc. (OTCQB:
RXMD) (“Progressive Care” or the “Company”), a personalized
healthcare services and technology company, is excited to announce
a new partnership with EagleForce Health, LLC to integrate its
proprietary telehealth platform (“myVax™”) and develop a platform
for the Company’s Digital Passport for COVID-19 Testing and
Vaccination results.
“The need for a digital passport to help manage our coming
post-pandemic environment is paramount, and we believe myVax™ can
develop into a market-leading solution to meet that need,” remarked
Alan Jay Weisberg, CEO and Chairman of Progressive Care. “This
partnership will allow Progressive Care to expand our telehealth
presence and scale more of our operations in a geographically
agnostic manner through significant exposure to one of the most
important opportunities defining the intermediate-term future in
the business economy: digital proof of vaccination.”
The myVax™ platform is expected to launch over the coming weeks
and to include complete patient scheduling, telehealth, and
tele-pharmacy platform services. “Our partnership with Progressive
Care is designed to focus on the COVID-19 digital passport roll-out
to support the Company’s first line health service providers who
see, touch, and bring solutions directly to the patient. Phase 1 of
the myVax™ platform launch will be made available to the patient
population well beyond the COVID 19 pandemic. The full scope of our
commitment to this partnership will bring transformational outcomes
to patient adherence and self-management of disease to the rapidly
growing Telehealth marketplace. We are so proud to have Progressive
Care as a partner,” said Stanley Campbell, CEO and Chairman of
EagleForce Health, LLC.
The platform will manage an individual’s COVID-19 Vaccine and
Test Journey documenting all transitions, including healthcare
appointments, billing, and telehealth services. This will also
include a Digital Passport or Digital Wallet that is QR-coded for
registration, verification, and documentation of COVID-19
vaccination and/or test results.
This is expected to provide a powerful tool for various
processes that the Company believes will come to depend upon
accurate real-time virus spread risk abatement, including merchants
such as cruise lines, airlines, sports venues,
high-population-density, manufacturing, packing, or shipping
facilities, and institutions such as school districts,
universities, court proceedings, public transportation systems, and
other service providers.
Mr. Weisberg added, “The COVID-19 digital passport roll-out will
be our Phase 1 service launch for the myVax™ platform; however, the
full scope of this partnership expands well beyond COVID-19 and is
expected to powerfully augment our overall positioning in the
rapidly growing Telehealth marketplace. We look forward to
providing further updates and additional detail in subsequent
communications.”
For more information about Progressive Care, please visit the
company’s website. Connect and stay in touch with us on social
media:
Progressive Care Inc.
https://www.progressivecareus.com/
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
https://www.pharmcorx.com/get-tested-now
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx
ClearMetrX
https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/
About Progressive Care
Progressive Care Inc. (OTCQB:
RXMD), through its subsidiaries, is a Florida health services
organization and provider of prescription pharmaceuticals,
compounded medications, provider of tele-pharmacy services, the
sale of anti-retroviral medications, medication therapy management
(MTM), the supply of prescription medications to long-term care
facilities, and health practice risk management.
About MyVax
MyVax™ National Immunization Management system is deployed and
scaled to serve as a single national platform for the emergency
authorization of the COVID-19 vaccines, the associated lab reports
as well as the daily routine management of other vaccines and
medications for chronic conditions. The national infrastructure
operates at every point-of-sale pharmacy with real-time alerting
functionality that reaches across state borders to assure the
safety and efficacy of all patients while enabling self-monitoring
and management of chronic conditions and medications. This platform
is designed to promote adherence and self-management of disease
including routine immunizations and preventive care with access to
care team through HIPAA compliant Telehealth platform. MyVax™ is
designed to provide every man, woman, and child access to their own
COVID-19 Vaccination Information and Medical Information for 25
years. MyVax™ allows the patient to own their own data and receive
real-time scheduling and alerts directly from any provider,
pharmacy, or payer from anyplace in the nation.
About EagleForce
EagleForce’s pedigree was established within the commercial and
government health sectors and is recognized as a leading technology
solutions company providing a broad range of eligibility systems
development, organizational and operational assistance to “Big Data
Analytics” processing, interoperability, predictive analytics, and
other IT functions. The Company’s evidence-based eligibility &
real-time monitoring systems have been deployed to solve some of
the biggest technology challenges in the world. Today, the
EagleForce solutions have been adopted by many leading healthcare
companies including pharmaceutical manufacturers, PBMs, chain
pharmacies and drug wholesalers. EagleForce Health delivers the
most advanced evidence-based clinical insights and business
intelligence for accurate and persistent information available
today. Leveraging the secure technology that has provided knowledge
and analytics to both the commercial and government industries for
many years, EagleForce Health brings this high pedigree of advanced
analytics, information sharing, security, and privacy to
healthcare.
Cautionary Disclosure Regarding Forward-Looking
Statements
Forward-Looking Statements contained herein that are not based
upon current or historical fact are forward-looking in nature and
constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such forward-looking statements reflect the
Company’s expectations about its future operating results,
performance, and opportunities that involve substantial risks and
uncertainties. When used herein, the words “anticipate,” “believe,”
“estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and
similar expressions, as they relate to Progressive Care Inc., its
subsidiaries, or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information currently available to the Company and are
subject to a number of risks, uncertainties, and other factors that
could cause the Company’s actual results, performance, prospects,
and opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
Public Relations Contact
Carlos Rangel
carlosr@pharmcorx.com
Progressive Care (QB) (USOTC:RXMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progressive Care (QB) (USOTC:RXMD)
Historical Stock Chart
From Apr 2023 to Apr 2024